Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

the U.S. Food and Drug Administration (FDA), demonstrated the following key results for XIENCE V at two years:

-- A 45 percent reduction in the risk of major adverse cardiac events

(MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for

TAXUS, p-value=0.004)*. MACE is an important composite clinical measure

of safety and efficacy outcomes for patients, defined as cardiac death,

heart attack (MI), or ischemia-driven target lesion revascularization

(TLR driven by lack of blood supply).

-- A 32 percent reduction in the risk of Target Vessel Failure (TVF,

cardiac events related to the treated vessel) compared to TAXUS

(10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.

TVF is a composite clinical measure of safety and efficacy outcomes

defined as cardiac death, heart attack (myocardial infarction or MI) or

target vessel revascularization (TVR).

-- A 40 percent reduction in the risk of ischemia-driven target lesion

revascularization (ID-TLR) as compared to TAXUS (4.6 percent for

XIENCE V vs. 7.5 percent for TAXUS, p-value=0.07)*.

-- Low rates of stent thrombosis between one and two years, defined as

very late stent thrombosis, per Academic Research Consortium (ARC)

definition of definite/probable stent thrombosis (0.3 percent for

XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol

(0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC

definitions of stent thrombosis were developed to eliminate variability

in the definitions across various drug eluting stent trials.

"From these results, it is clear that XIENCE V can deliver sustained benefits to patients over the long term," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We continue to be pleased with the way XIENCE V is performing, w

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
(Date:10/9/2015)... 2015 Adheron Therapeutics, a privately held ... , United States , ... acquired by Roche.  Adheron Therapeutics has developed a ... a cell surface protein called Cadherin-11 in order ... inflammatory and autoimmune diseases such as rheumatoid arthritis ...
(Date:10/8/2015)... , October 9, 2015 ... or diagnostic colonoscopy. The NOCT study also assessed ... NER1006. --> ® ) in adult ... NOCT study also assessed the compliance, safety, patient ... Norgine today announced positive top line results for ...
(Date:10/8/2015)... 8, 2015  Trovagene, Inc., (NASDAQ:   TROV) ... the presentation of results from a field experience ... Monitoring SM (PCM) platform to accurately identify ... to determine appropriate therapy for patients. Mark ... is delivering the results today in an oral ...
Breaking Medicine Technology:
... Va., Aug. 8, 2011 Science Applications International ... has completed the acquisition of Vitalize Consulting Solutions ... and information technology (IT) services for healthcare enterprises. ... the commercial hospital market that are implementing electronic ...
... HOPKINTON, Mass., Aug. 8, 2011 Caliper Life Sciences, ... it has favorably settled two lawsuits with Carestream Health, ... February 2010, Caliper, its wholly owned subsidiary, Xenogen, and ... its instrument systems induced infringement of seven imaging patents ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental ... teenagers facing mental illness, the stigma associated with mental illness causes many to hide ... understands the importance of supporting teens with mental illness , providing teens with ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... placement counseling, recently opened its newest office in Maryland – its Bethesda ... with a background as a project management technology consultant to many of the ...
(Date:10/9/2015)... ... ... race options will be available for the Run 4 Recovery sponsored by WestBridge ... 4810 North Himes Avenue, in Tampa. The family friendly event will start with opening remarks ... a one-mile walk, followed by an award ceremony at 10 a.m. As part of a ...
(Date:10/9/2015)... ... October 09, 2015 , ... Safe Space, a non-profit organization ... launched a new website to mark Domestic Violence Awareness Month. , This ... immediately, whether through an emergency hotline, support group, or shelter. The revamped site ...
(Date:10/9/2015)... ... October 09, 2015 , ... Bag Tags Inc. will provide ... the media at the annual IRONMAN World Championship in Kailua-Kona, Hawaii, this ... which has taken place in Hawaii every year since 1978. , As part ...
Breaking Medicine News(10 mins):
... Dec. 18 Cyberonics, Inc. (Nasdaq:,CYBX) announced that ... an agreement with Ethicon Endo-Surgery granting exclusive rights ... vagus nerve,stimulation (VNS) for the treatment of obesity ... patients., Ethicon Endo-Surgery has agreed to pay ...
... HILL, N.C., Dec. 18 Despite all the ... a long and,expensive trip from the lab to ... money pay off, best-in-class pharmaceutical companies have learned,to ... process,according to research from Best Practices, LLC., ...
... team of scientists that includes a Saint Louis University ... of brain diseases that include multiple sclerosis, Alzheimers disease, ... Lancet Neurology. , Their review article, which focuses on ... available in an early online edition of the prestigious ...
... stick to the same guidelines about alcohol consumption as ... to the over 65s, and may even bring health ... School in the South West of England. , Researchers ... in England and the US and looked at the ...
... Hemodynamic and Implantability Characteristics, MINNEAPOLIS, Dec. ... ), manufacturer and marketer of state-of-the-art cardiac,surgery ... and Drug,Administration (FDA) approval for the ATS ... ), The ATS AP360 ...
... will be running the,story December 17th and 18th on ... TO A NEW ROBOT THAT MEASURES AND MIXES THEIR,TREATMENT., ... and,a patient were interviewed by CBS News. The story ... syringes and IV bags.,University of Colorado Hospital and Baylor ...
Cached Medicine News:
... assay is a sensitive, simple ... permits the detection of all ... and can distinguish between ... P. vivax . In addition, ...
Malaria Pf/Pv Assay Range...
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (2 line, P.f.-HRP2 Test)...
Medicine Products: